Literature DB >> 8109918

In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.

M D Huband1, M A Cohen, M A Meservey, G E Roland, S L Yoder, M E Dazer, J M Domagala.   

Abstract

PD 138312 and PD 140248 are new quinolones with high in vitro activities against a wide spectrum of bacterial species, notably including gram-positive isolates. The respective MICs (in micrograms per milliliter) of PD 138312 and PD 140248 capable of inhibiting > or = 90% of the strains were < or = 0.06 and < or = 0.06 for oxacillin-susceptible and -resistant staphylococci, streptococci (including Streptococcus pyogenes, S. agalactiae, S. pneumoniae, and viridans group streptococci), Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae; 0.125 and 0.03 for Legionella pneumophila; 0.25 and 0.125 for Listeria monocytogenes; 0.25 and 0.25 for Enterococcus faecalis; 0.5 and 0.06 for anaerobic gram-positive cocci; 0.5 and 0.25 for Acinetobacter spp.; 0.5 and 0.5 for members of the family Enterobacteriaceae (excluding Serratia marcescens); 2 and 0.5 for Bacteroides fragilis; 2 and 2 for Serratia marcescens and ciprofloxacin-resistant staphylococci; and 8 and 4 for Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109918      PMCID: PMC192739          DOI: 10.1128/AAC.37.12.2563

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids.

Authors:  J P Sanchez; J M Domagala; S E Hagen; C L Heifetz; M P Hutt; J B Nichols; A K Trehan
Journal:  J Med Chem       Date:  1988-05       Impact factor: 7.446

2.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Infectious complications with respiratory pathogens despite ciprofloxacin therapy.

Authors:  B L Lee; A M Padula; R C Kimbrough; S R Jones; R E Chaisson; J Mills; M A Sande
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

4.  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.

Authors:  J M Domagala; L D Hanna; C L Heifetz; M P Hutt; T F Mich; J P Sanchez; M Solomon
Journal:  J Med Chem       Date:  1986-03       Impact factor: 7.446

Review 5.  A review of the antimicrobial activity of the fluoroquinolones.

Authors:  P Maple; W Brumfitt; J M Hamilton-Miller
Journal:  J Chemother       Date:  1990-10       Impact factor: 1.714

6.  Comparison of microdilution and agar dilution procedures for testing antibiotic susceptibility of Neisseria gonorrhoeae.

Authors:  M A Shapiro; C L Heifetz; J C Sesnie
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

7.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1- pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy.

Authors:  J M Domagala; S E Hagen; T Joannides; J S Kiely; E Laborde; M C Schroeder; J A Sesnie; M A Shapiro; M J Suto; S Vanderroest
Journal:  J Med Chem       Date:  1993-04-02       Impact factor: 7.446

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  5 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 2.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 3.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.

Authors:  M A Cohen; S L Yoder; M D Huband; G E Roland; C L Courtney
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

5.  In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency.

Authors:  M A Shapiro; J A Dever; E T Joannides; J C Sesnie; S R Vanderroest
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.